Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

HLA B7 Antikörper

HLA B7 Reaktivität: Human, Non-Human Primate FACS Wirt: Maus Monoclonal BB7-1 unconjugated
Produktnummer ABIN1027673
  • Target Alle HLA B7 Antikörper anzeigen
    HLA B7 (HLA Class I B7 Alpha (HLA B7))
    Reaktivität
    • 13
    • 3
    • 2
    • 2
    • 1
    Human, Non-Human Primate
    Wirt
    • 11
    • 2
    Maus
    Klonalität
    • 11
    • 2
    Monoklonal
    Konjugat
    • 7
    • 4
    • 2
    Dieser HLA B7 Antikörper ist unkonjugiert
    Applikation
    • 9
    • 3
    • 2
    • 1
    • 1
    Flow Cytometry (FACS)
    Spezifität
    The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
    Kreuzreaktivität (Details)
    Human, Non-Human Primates
    Aufreinigung
    Purified by protein-A affinity chromatography.
    Reinheit
    > 95 % (by SDS-PAGE)
    Immunogen
    Papain solubilised HLA-A2, B7
    Klon
    BB7-1
    Isotyp
    IgG1
    Top Product
    Discover our top product HLA B7 Primärantikörper
  • Applikationshinweise
    Flow cytometry: Recommended dilution: 1-4 μg/mL.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    1 mg/mL
    Buffer
    Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Handhabung
    Do not freeze.
    Lagerung
    4 °C
    Informationen zur Lagerung
    Store at 2-8°C. Do not freeze.
  • Cortez-Gonzalez, Sidney, Adotevi, Sette, Millard, Lemonnier, Langlade-Demoyen, Zanetti: "Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).

    de la Salle, Saulquin, Mansour, Klayme, Fricker, Zimmer, Cazenave, Hanau, Bonneville, Houssaint, Lefranc, Naman: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." in: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).

    Rini, Selk, Vogelzang: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).

    Trapani, Vaughan, Tait, McKenzie: "Immunoradiometric assay for the rapid detection of HLA-B27." in: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).

    Storkus, Alexander, Payne, Dawson, Cresswell: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).

  • Target
    HLA B7 (HLA Class I B7 Alpha (HLA B7))
    Andere Bezeichnung
    HLA-B7 (HLA B7 Produkte)
    Synonyme
    AS antikoerper, HLAB antikoerper, SPDA1 antikoerper, major histocompatibility complex, class I, B antikoerper, HLA-B antikoerper
    Hintergrund
    HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.
    Pathways
    Human Leukocyte Antigen (HLA) in Adaptive Immune Response
Sie sind hier:
Kundenservice